These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28419087)

  • 1. Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA.
    Duong C; Yoshida S; Chen C; Barisone G; Diaz E; Li Y; Beckett L; Chung J; Antony R; Nolta J; Nitin N; Satake N
    Pediatr Res; 2017 Sep; 82(3):527-535. PubMed ID: 28419087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.
    Satake N; Duong C; Chen C; Barisone GA; Diaz E; Tuscano J; Rocke DM; Nolta J; Nitin N
    Br J Haematol; 2014 Nov; 167(4):487-99. PubMed ID: 25196579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma.
    Yoshida S; Duong C; Oestergaard M; Fazio M; Chen C; Peralta R; Guo S; Seth PP; Li Y; Beckett L; Nitin N; Satake N
    Nanomedicine; 2020 Feb; 24():102127. PubMed ID: 31783139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells.
    Meng J; Tagalakis AD; Hart SL
    Sci Rep; 2020 Jan; 10(1):1046. PubMed ID: 31974512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma.
    Penter L; Maier B; Frede U; Hackner B; Carell T; Hagemeier C; Truss M
    Target Oncol; 2015 Dec; 10(4):523-33. PubMed ID: 25559288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
    Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD146 is a potential immunotarget for neuroblastoma.
    Obu S; Umeda K; Ueno H; Sonoda M; Tasaka K; Ogata H; Kouzuki K; Nodomi S; Saida S; Kato I; Hiramatsu H; Okamoto T; Ogawa E; Okajima H; Morita K; Kamikubo Y; Kawaguchi K; Watanabe K; Iwafuchi H; Yagyu S; Iehara T; Hosoi H; Nakahata T; Adachi S; Uemoto S; Heike T; Takita J
    Cancer Sci; 2021 Nov; 112(11):4617-4626. PubMed ID: 34464480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo.
    Jiang R; Xue S; Jin Z
    Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran.
    Tietze N; Pelisek J; Philipp A; Roedl W; Merdan T; Tarcha P; Ogris M; Wagner E
    Oligonucleotides; 2008 Jun; 18(2):161-74. PubMed ID: 18637733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MXD3 regulation of DAOY cell proliferation dictated by time course of activation.
    Ngo T; Barisone GA; Lam KS; Dίaz E
    BMC Cell Biol; 2014 Jul; 15():30. PubMed ID: 25053245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
    Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
    Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of MXD3 induces apoptosis of Reh human precursor B acute lymphoblastic leukemia cells.
    Barisone GA; Satake N; Lewis C; Duong C; Chen C; Lam KS; Nolta J; Dίaz E
    Blood Cells Mol Dis; 2015 Apr; 54(4):329-35. PubMed ID: 25554682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification.
    Nara K; Kusafuka T; Yoneda A; Oue T; Sangkhathat S; Fukuzawa M
    Int J Oncol; 2007 May; 30(5):1189-96. PubMed ID: 17390021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapy.
    Schulte JH; Schramm A; Pressel T; Klein-Hitpass L; Kremens B; Eils J; Havers W; Eggert A
    Klin Padiatr; 2003; 215(6):298-302. PubMed ID: 14677092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
    Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
    Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
    Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
    Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.